Key Takeaways
- Volume up, value down: Volume grew ~15% QoQ, but value fell ~8% as commodity-linked raw material and finished product prices declined.
- Isostearic Acid is the margin story: Initial stabilization losses and high utility costs weighed on EBITDA margins this quarter, but the plant is stabilizing and management expects margins to recover to 15% for FY25.
- Prime product mix hits 85%: Realization from high-value products like Linoleic, Dimer, Toco and Isostearic Acid reached ~85% of sales value, up from ~75% earlier, driven by trial Isostearic processing.
- Export push begins: Full container loads of Isostearic Acid were exported to Europe in March 2024, with export mix expected to rise from 5% to 12-15% in FY25.
- What to watch next quarter: Whether Isostearic Acid stabilization completes by the September outer limit, the pace of the quarterly margin inch-up toward 15%, and any update on the new raw material pilot plant.
Isostearic Acid: Stabilization & Ramp-Up
- Stabilization drag: Initial losses from material loss and high utility costs while establishing desired quality levels marginally impacted EBITDA margins this quarter.
- Quality achieved: The quality manufactured now matches any product available in the market made by European or US-based manufacturers.
- Demand pull exists: The company has more orders than it can currently produce; the plant is stabilizing, which is taking time.
- Full capacity timeline: Management expects to reach full capacity utilization by the end of 2024, with 100% stabilization by September 2024 at the outer limit.
- Export milestone: Full container loads were exported to Europe in March 2024, and management expects fairly good sales volumes in FY25.
- Pricing undisclosed: Management declined to share Isostearic Acid realizations or gross margin estimates when asked by analysts.
Nahoosh Jariwala: "In fact, we have currently more orders than what we can produce. Plant is stabilizing, so that is taking little time."
Margin Trajectory & Recovery
- The 15% target: Management expects to achieve an EBITDA margin of 15% for FY25, improving on a quarter-to-quarter basis, with Q4 exit margin certainly higher than 15% to average 15% for the year.
- Stabilization costs unquantified: Management declined to quantify the one-time stabilization cost for Isostearic Acid in FY24, describing it as a longer period of losses rather than a discrete cost, and said it was not separately worked out.
- Dimer Acid is not the whole story: Dimer Acid contributes only 25% of total value; raw material costs and demand for other fatty acids also drive overall EBITDA performance.
- Forward integration to protect margins: Projects under development are not capital intensive and will not add much top line, but will add bottom line and insulate the company for the future.
Rajen Jhaveri: "EBITDA margin of the company is not fully dependent on Dimer Acid; it is only contributing 25% in terms of value."
Volume Growth & Demand Environment
- Sustained volume trajectory: The company has achieved continuous volume growth since FY22, with FY24 volumes growing ~15% year-on-year.
- Paint industry outperformance: While the paint industry grew ~10% overall, Fairchem achieved 15% volume growth, retaining all old customers and adding new ones.
- Grasim approval secured: Fairchem's product has been approved by Grasim, and the company now supplies material to all five large paint customers.
- China dumping over: Management stated that Chinese price dumping stopped in the first and second quarters long back, and there is no dumping from China anymore.
- Dimer Acid pricing pressure eased: Fairchem had to match import prices when China pricing was coming off, but that pressure has now abated.
- October-December softness: The prior quarter had seen an issue of lack of demand, which has since normalized.
Product Mix & New Developments
- Prime product shift: Realization from prime products reached ~85% of total sales in value terms, up from ~75% earlier, driven by increased Isostearic Acid processing on a trial basis.
- New raw material project: R&D work is complete and a pilot plant has been purchased; lab-level results are encouraging, and management expects to provide an update by the end of this year.
- End applications: The new product targets high-value applications in lubricants and other segments, is biodegradable, and has no Indian manufacturer with only 3-4 players globally.
- Linoleic Acid forward integration: Potential exists and the company is already working on it.
- Commercialization timeline: Management does not expect commercialization of the new raw material project this year; more details expected in the last quarter.
Rajen Jhaveri: "So in pull and push theory of business, there is a pull for this Isostearic thing, we are not required to push, we are only required to make the Isostearic Acid."
Capacity, Capex & Exports
- No old-product capacity expansion: No capex plan exists for expanding capacity of old products this year; management is evaluating options including upgrading products rather than only volume expansion.
- Utilization target: The company is targeting 90% utilization of existing capacity during FY25.
- Volume growth outlook: Given current capacity utilization, ~15% to 20% volume growth is doable for the next ~12 months.
- Export mix shift: Exports will gradually increase from the current 5% and may exceed 10% or reach 12% to 15% in FY25.
- Forward integration capex: Will be funded entirely through internal accruals with no long-term debt; the amounts will not be substantial.
Rajen Jhaveri: "Any forward integration projects are not going to be that capital intensive neither at the same time they won't add too much of top line, but they'll add the bottom line. That would insulate the company for future."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Isostearic Acid stabilization | 100% stabilized | By September 2024 (outer limit) |
| Isostearic Acid capacity utilization | Full operation, full capacity utilization | By end of 2024 |
| EBITDA margin | 15% for full year, improving quarter-on-quarter; Q4 exit higher than 15% | FY25 |
| Volume growth | 15% to 20% growth | Next ~12 months |
| Capacity utilization | 90% of existing capacity | FY25 |
| Export mix | Rise from 5% to 12-15% | FY25 |
| New raw material project update | Able to say something meaningful | By end of 2024 |
| Forward integration capex | Funded via internal accruals only, no long-term loans | Ongoing |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | ₹161 crores, +6% YoY |
| EBITDA | ₹19 crores, -2% YoY |
| EBITDA margin | 11.71% |
| Net profit | ~₹12 crores, flat YoY |
| Revenue from operations (FY24) | ₹622 crores, -4% YoY |
| EBITDA (FY24) | ₹67 crores, -7.5% YoY |
| EBITDA margin (FY24) | 10.78% |
| Net profit (FY24) | ~₹41 crores, -7% YoY |
| Volume growth (QoQ) | ~15% across all products |
| Value terms change (QoQ) | ~-8%, due to decrease in raw material and finished product prices |
| Raw material quantity processed | 19,000 tons |
| Raw material quantity processed (FY24) | 65,000 metric tons |
| Prime products share of total sales (value) | ~85%, including Linoleic, Dimer, Toco, Isostearic and other fatty acids |
| Linoleic Acid share of total sales | 46% |
| Dimer Acid share of total sales | 27% |
| Export mix | ~5% of total sales |
| Dimer Acid market share (India) | ~70%, greater than two-thirds of total India market |
| Capacity utilization (Fatty Acid business, FY24) | >80%, based on 80,000 metric tons earmarked capacity |
| Capacity utilization target (FY25) | 90% |
| Volume growth target (FY25) | 10% to 15% quantity growth |
| EBITDA margin target (FY25) | 15%, expected to be achieved on a full-year basis, improving quarter-to-quarter |
| Export mix expectation (FY25) | exceeding 10%, may reach 12% to 15% |